Ambrx Inc., a clinical stage biopharmaceutical company focused on discovering and developing first-in-class and best-in-class optimized protein therapeutics known as bio-conjugates, and Zhejiang Hisun Pharmaceutical Company Ltd. today announced a collaboration for the development and commercialization of bispecifics based on Ambrx technology for the treatment of cancer.
Hisun will have commercial rights to the products in China, while Ambrx will retain commercial rights outside of China and will be entitled to receive royalties on sales of the products in China. Hisun will manufacture the product to cGMP standards for clinical and commercial supplies on a global basis.
“This is a milestone for our company and a significant opportunity for us with Hisun as we develop bispecifics using our technology platform,” noted Lawson Macartney, Ph.D., Chief Executive Officer of Ambrx. “Hisun represents a strong strategic partner with the right regulatory and manufacturing expertise. We believe that this collaboration is additional validation of our technology platform and its potential for many clinical applications.”
“We are excited to partner with Ambrx, a prominent biotechnology company with a robust technology platform for the development of bispecifics. This partnership will help Hisun to expand our pipeline and advance our position in the biopharmaceutical industry across the globe,” added Hua Bai, Chief Executive Officer and Chairman of Hisun.
Published in: Ambrx Inc. website